+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026

  • ID: 4995730
  • Report
  • March 2020
  • Region: Global
  • 330 Pages
  • Kuick Research
1 of 4
The Global Cancer Generic Drug Market to Witness Exponential Growth as Drug Sales are Expected to Increase its Sales Beyond US$ 55 Billion by 2026

FEATURED COMPANIES

  • Accord Healthcare
  • Amneal Pharmaceuticals
  • Dr. Reddy Laboratories
  • Glenmark
  • MSN Group
  • Pfizer (Hospira)
  • MORE

"Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:

  • Global Cancer Generics Market Trend Analysis
  • Global Cancer Generics Market Opportunity: > USD 55 Billion By 2026
  • Global Generics Market Growth 2018-2026: > 130%
  • Global Cancer Generics Market Growth 2018-2026: 200%
  • Reimbursement Policies & the Coverage Strategies By Countries
  • Cancer Generic Drugs Availability, Dosage & Price Analysis By Segment
  • Comprehensive Insight On Cancer Generics Drugs: 43 Generics

Since the arrival of the generic drugs approach 30 years ago, the market is showing a tremendous elevation in the consumption rate of the cancer generics across the globe: the reasons being the uncontrollably growing population and the unmanageable crisis of cancer mortality. The major advantage that is largely associated with the accelerated generics drug market is the fact that the development of the drug doesn’t require prolonged period of time. The ease in developing the drug and the high adoption rate by the patients contribute largely to the established markets of cancer generics.

"The Global Cancer Generic Drug Market To Witness Exponential Growth As Drug Sales Are Expected To Increase Its Sales Beyond US$ 55 Billion By 2026"

It is well-witnessed fact that the survival rate of the cancer patients have experienced a positive trail since the advent of the cancer generic drugs in the market. Patients and clinicians, whenever possible are more inclined towards the utilization of generic drugs in their treatment, as it is more segmented towards the patients that are not able to consume branded drugs, which however comprises of the maximum population around the globe. The necessity of generic drugs in the society and the upsurge it has been experiencing since its arrival at the global pharmaceutical landscape represents a stage of the market which is highly dominated by the cancer generics drugs.

Cancer generics market gets highlighted by the minimal efforts drug makers have to put and the maximum advantages that the patients will receive. The most important and the fundamental advantages that are received by the approach is that it provides the bioequivalent form of the original branded drug i.e. in same dosage, mode of administration and the effectiveness in a way cheaper price. Such advantages are making the whole percentage of patients with no or less hope towards a more suitable and decent method by providing a privileged from of treatment.  

The increasing consumption of generic drugs and the mounting trust of patient towards cancer generics drugs are going to play a very important role in the market expansion. A big contribution for the splendid market growth rate is also provided by the governing bodies of the respective country. The impositions made by the governing bodies for clinicians in dispensing generic drugs have caused an accelerated growth in the market size. The market of cancer generics is also escalating by the fact that the number of pharmaceuticals players interested in manufacturing generic drugs have been increasing.

The research report “Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026” provides an in-depth analysis about the trends that are followed by the cancer generics market at the global and regional level as well as the revolutionizing strategies that have been adopted and supported by the governing and regulatory bodies around the globe. The research report is a result of the extensive study conducted by analyzing the global companies for cancer generics. The opinions from the different generic drug companies have been gathered to successfully deliver the latest trends and opportunities and the future prospects on commercials for the market of cancer generics.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Accord Healthcare
  • Amneal Pharmaceuticals
  • Dr. Reddy Laboratories
  • Glenmark
  • MSN Group
  • Pfizer (Hospira)
  • MORE

1. Introduction to Cancer Generics
1.1 Overview
1.2 The Growing Need for Cancer Generics over Branded Drugs
1.2.1 Reduced Developmental Cost Leading to Cost-Efficient Cancer Generics
1.2.2 Reduced Timeline Leading to Cost-Efficient Cancer Generics Development
1.2.3 Cancer Generics Representing Same Effectiveness as of Branded Drugs

2. Global Cancer Generics Market Trend Analysis
2.1 Overview
2.2 Current Market Scenario
2.3 Cancer Generics Market Future Outlook

3. US - Current Market Status of Cancer Generics
3.1 Significant Facts & Figures Prevailing Cancer Generics Market
3.2 US Cancer Generics Market Trends & Opportunities
3.2.1 Guidelines, Policies & Procedures by the FDA for the US Market

4. Japan - Current Cancer Generics Market Insight
4.1 Factors Propelling the Growth of Cancer Generics in Japan
4.2 Trends & Opportunities of Cancer Generics Market in Japan
4.2.1 Cancer Generic Drugs Prescription & Dispensing

5. Europe - Key Asset to Cancer Generics Market Progression
5.1 Evaluation of Facts Associated with Cancer Generics Growth
5.2 Cancer Generics Market Current Trends & Opportunities
5.2.1 Europe Government Regulations for Cancer Generics Market Progress
5.2.2 Germany - Current Cancer Generics Market Trends & Opportunities
5.2.3 France - Current Cancer Generics Market Trends & Opportunity
5.2.4 UK - Current Cancer Generics Market Trends & Opportunities
5.2.5 Belgium - Current Cancer Generics Market Trends & Opportunities
5.2.6 Others - Current Cancer Generics Market Trends & Opportunities

6. China - As an Emerged Cancer Generic Market in Asia
6.1 Simulating Facts & Figures for Chinese Cancer Generics Market
6.2 Trends & Opportunities Linked with China’s Cancer Generics Market
6.2.1 Laws & Regulating Supporting Cancer Generics Market in China

7. India - A Major Contributor to the Global Generics Market
7.1 Fact Sheets Related to Cancer Generics Growth in India
7.2 Trends & Opportunities for India’s Cancer Generics Market
7.2.1 Guidelines & Laws for Implementing Generic Drugs in India

8. South Korea - Cancer Generics Market Current Insight
8.1 Cancer Generics Drug Market Expansion Facts & Figures
8.2 Provoking Trends & Opportunities for South Korean Cancer Generics Market

9. Russia - Cancer Generics Market Scenario
9.1 Facts Encouraging the Current Market Situation in Russia
9.2 Trends & Opportunities Followed by Russian Cancer Generics Market
9.2.1 Rules & Regulations Boosting the Current Market of Cancer Generics

10. Reimbursement Policies & the Coverage Strategies
10.1 US
10.2 Europe
10.3 India
10.4 Japan
10.5 China
10.6 Russia

11. Price Analysis for Branded Drugs VS Generic Drugs

12. Breast Cancer Generic Drugs - Availability, Dosage & Price Analysis
12.1 Letrozole
12.2 Anastrazole
12.3 Exemestane
12.4 Epirubicine
12.5 Toremifene
12.6 Fulvestrant
12.7 Megestrol

13. Colorectal Cancer Generic Drugs - Availability, Dosage & Price Analysis
13.1 Irinotecan
13.2 Oxaliplatin

14. Leukemia Generic Drugs - Availability, Dosage & Price Analysis
14.1 Clofarabin
14.2 Imatinib
14.3 Mercaptopurine
14.4 Idarubicin
14.5 Daunorubicin
14.6 Cytarabin

15. Prostate Cancer Generic Drugs - Availability, Dosage & Price Analysis
15.1 Abiraterone
15.2 Bicalutamide
15.3 Nilutamide
15.4 Flutamide

16. Skin Cancer Generic Drugs - Availability, Dosage & Price Analysis
16.1 Imiquimod Topical Cream
16.2 Fluorouracil Topical

17. Lung Cancer Generic Drugs - Availability, Dosage & Price Analysis
17.1 Vinorelbine

18. Brain Tumor Generic Drugs - Availability, Dosage & Price Analysis
18.1 Temozolomide

19. Renal Cell Carcinoma Generic Drug - Availability, Dosage & Price Analysis
19.1 Temsirolimus

20. Generic Drugs for Multiple Cancers - Availability, Dosage & Price Analysis
20.1 Erlotinib
20.2 Dactinomycin
20.3 Ifosfamide
20.4 Romidepsin
20.5 Everolimus
20.6 Capecitabine
20.7 Gemcitabine
20.8 Paclitaxel
20.9 Fluorouracil
20.10 Docetaxel
20.11 Methotrexate
20.12 Cyclophosphamide
20.13 Vincristine
20.14 Etoposide
20.15 Mitoxantrone
20.16 Carmustine
20.17 Dacarbazine
20.18 Mitomycin
20.19 Bleomycin

21. Global Cancer Generics Market Dynamics
21.1 Factors Favoring the Growth of Cancer Generics Market
21.2 Factors Restraining the Growth of Cancer Generics Market

22. Competitive Landscape
22.1 Teva Pharmaceuticals
22.2 Accord Healthcare
22.3 Amneal Pharmaceuticals
22.4 Mylan
22.5 Dr. Reddy Laboratories
22.6 Bedford Pharma
22.7 Hikma
22.8 Cipla
22.9 Shilpa Medicare
22.10 Fresenius Kabi
22.11 Zydus Pharmaceuticals
22.12 Neopharm
22.13 Netco
22.14 Mayne Pharma
22.15 Alvogen
22.16 Glenmark
22.17 HBT Labs
22.18 Gland
22.19 Qilu Pharmaceuticals
22.20 Akorn Pharmaceuticals
22.21 MSN Group
22.22 Wockhardt
22.23 Rising Pharma
22.24 Apotex
22.25 Taro Pharmaceuticals
22.26 Sun Pharma
22.27 Alkem Laboratories
22.28 Endo Pharma
22.29 Pfizer (Hospira)

List of Figures

Figure 1-1: Objectives of Cancer Generics for Cancer Patients
Figure 1-2: Gleevec - Comparison between Branded & Generic Drug Price for 30 Tablets of 400 mg (US$), January’2020
Figure 1-3: Key Differences Between Branded & Generic Drugs
Figure 1-4: Global - Cost of Branded Drug vs. Generic Drug Development, (US$ Million)
Figure 1-5:  Cancer Generic vs. Branded Developmental Timeline
Figure 1-6: Developmental Timeline for Branded Drug & Generic Drug (Years)
Figure 2-1: Global –Pharmaceutical Market (US$ Trillion), 2018 - 2026
Figure 2-2: Global – Size of Total Cancer Market vs. Cancer Generics Market (US$ Billion), 2018
Figure 2-3: Global – Size of Total Cancer Market vs. Cancer Generics Market (%), 2018
Figure 2-4: Global – Estimated Cancer Market vs. Cancer Generics Market (US$ Billion), 2018 - 2026
Figure 2-5: Global – Expected Generics Market Size (US$ Billion), 2018 - 2025
Figure 2-6: Global – Market Size of Cancer Generics (US$ Billion), 2018 & 2026
Figure 2-7: Global – Estimated Market Size of Cancer Generics (US$ Billion), 2018 – 2026
Figure 3-1: US – Total Cancer Deaths, 2018 & 2019
Figure 3-2: US – Cancer Mortality Rate by Gender per 100,000 Person, 2018
Figure 3-3: US – Cancer Statistics of Children of age 0 – 9 Years, 2017
Figure 3-4: US – National Expenditure for Cancer Care (US$ Billion), 2015 & 2017
Figure 3-5: US – Population Statistics (Million), 2018 & 2019
Figure 3-6: US vs. ROW Population Statistics (%), 2019
Figure 3-7: US – Prescription Share of Generic Drugs filled at less than US$ 20 (%), 2018
Figure 3-8: US – Average Branded & Generic Drug Copy (US$), 2018
Figure 3-9: US – Generic Medicine Utilization by Age (%), 2017
Figure 3-10: US – Top Generic Drug Pharmaceutical Companies, 2019
Figure 3-11: US – Expected Generic Drug Market Size (US$ Billion), 2018 - 2025
Figure 3-12: US – Market of Prescription Spending (%), 2017
Figure 3-13: US – Minimum & Maximum Generic Drug Prescriptions out of every 10 Prescriptions, 2017
Figure 4-1: Japan – Cancer Statistics (Million), 2018
Figure 4-2: Japan – Population Statistics (Million), 2018 - 2020
Figure 4-3: Japan vs. ROW Population Statistics (%), 2019
Figure 4-4: Japan – Expected Penetration of Generics Market in the Country US$ Billion%), 2017 & 2018
Figure 4-5: Japan – Top Cancer Generics Pharmaceuticals
Figure 4-6: Japan – Estimated  Cancer Market Size (US$ Million), 2018 - 2026
Figure 4-7: Japan – Expected Generic Market Size (US$ Billion), 2018 - 2026
Figure 4-8: Japan – Market Representation by Generic Drugs (%), 2020
Figure 4-9: Total Cancer Drug Market Global vs. Japan Cancer Drug Market (US$ Billion), 2019
Figure 4-10: Generics Drug Market - Global vs. Japan (US$ Billion), 2019
Figure 5-1: Europe – Population Statistics (Million), 2017 - 2019
Figure 5-2: Europe – Population Statistics by Region (Million), 2020
Figure 5-3: Europe vs. ROW Population Statistics (%), 2019
Figure 5-4: Europe vs. Global Population (Million), 2018 & 2019
Figure 5-5: Europe – Cancer Statistics (Million), 2018
Figure 5-6: Europe – Pharmaceutical Sales (US$ Billion), 2018 - 2020
Figure 5-7: Europe – Top Cancer Generics Pharmaceutical Companies
Figure 5-8: Germany – Population Statistics (Million), 2018 - 2020
Figure 5-9: Germany – Cancer Statistics (Million), 2018
Figure 5-10: Germany – Expected Total Pharmaceutical Market (US$ Billion), 2018 - 2026
Figure 5-11: Germany – Expected Generics Market Size (US$ Billion), 2018 – 2026
Figure 5-12: Germany – Penetration of Generics Market into Total Pharmaceutical Market (%), 2019
Figure 5-13: Germany – Driving Factors for Generics Market
Figure 5-14: France – Population Statistics (Million), 2017 - 2019
Figure 5-15: France – Cancer Statistics (Million), 2018
Figure 5-16: France – Expected Total Pharmaceutical Market (US$ Billion), 2018 - 2026
Figure 5-17: France – Expected Generics Market Size (US$ Billion), 2018 - 2026
Figure 5-18: UK – Population Statistics (Million), 2017 - 2019
Figure 5-19: UK – Cancer Statistics (Million), 2018
Figure 5-20: UK – Expected Pharmaceutical Market Size (US$ Billion), 2018 - 2026
Figure 5-21: UK – Expected Number of Generic Subscriptions Fulfilled (Million), 2018 - 2026
Figure 5-22: Belgium – Estimated Pharmaceutical Market Size (US$ Billion), 2018 - 2026
Figure 5-23: Belgium – Expected Generic Market (US$ Million), 2018 - 2026
Figure 5-24: Belgium – Penetration of Generic Market in Total Pharmaceutical Market, 2019
Figure 6-1: China – Population Statistics (Million), 2016 - 2020
Figure 6-2: China vs. Global Population Statistics (%), 2019
Figure 6-3: China – Cancer Statistics (Million), 2018
Figure 6-4: China – Registered Drugs (%), 2019
Figure 6-5: China – Generic Drug Application Procedure
Figure 6-6: China – Top Pharmaceutical Companies
Figure 6-7: China – Expected Total Pharmaceutical Market (US$ Billion), 2018 - 2025
Figure 6-8: China – Estimated Cancer Market Size (US$ Million), 2018 - 2026
Figure 6-9: China – Estimated Generics Market Size (US$ Billion), 2018 - 2026
Figure 6-10: China –Pharmaceutical Market vs. Generics Market (US$ Billion), 2018 - 2026
Figure 7-1: India – Population Statistics (Million), 2017 - 2019
Figure 7-2: Total Population vs. Population of India (%), 2019
Figure 7-3: India – Cancer Statistics (Million), 2018
Figure 7-4: India – Expected Pharmaceutical Market Size (US$ Billion), 2018 - 2026
Figure 7-5: India – Percentage of India’s Pharmaceutical Market vs. Global, 2018
Figure 7-6: India – Expected Pharmaceutical Export Market (US$ Billion), 2018 - 2025
Figure 7-7: India – Estimated Cancer Drug Market (US$ Billion), 2018 - 2026
Figure 7-8: India – Top Generic Drug Pharmaceutical Companies
Figure 7-9: India – Expected Generic Market Size (US$ Billion), 2018 – 2026
Figure 7-10: India – Exports of Generics (%), 2019
Figure 7-11: Ibrunat – Price of Branded Drug vs. Generic Drug (US$), 2019
Figure 7-12: Hertab – Price of Branded Drug vs. Generic Drug (US$), 2019
Figure 8-1: South Korea – Population Statistics (Million), 2017 - 2019
Figure 8-2: South Korea – Cancer Statistics (Million), 2018
Figure 8-3: South Korea – Countries Buying Korean Drugs (US$ Million), 2018
Figure 8-4: South Korea – Top Generic Drug Pharmaceutical Companies
Figure 8-5: South Korea – Estimated Pharmaceutical Market (US$ Billion), 2018 - 2026
Figure 8-6: South Korea – Cancer Drug Market Estimates (US$ Billion), 2018 - 2026
Figure 8-7: South Korea – Expected Generics Market Size (US$ Billion), 2018 - 2026
Figure 9-1: Russia – Population Statistics (Million), 2017 - 2019
Figure 9-2: Russia – Cancer Statistics (Million), 2018
Figure 9-3: Russia – Demographics of Cancer Deaths (Million), 2018 & 2035
Figure 9-4: Russia – Estimated  Pharmaceutical Market Size (US$ Billion), 2018 - 2026
Figure 9-5: Russia – Domestic vs. International Pharmaceutical Volume Share (%), 2019
Figure 9-6: Russia – Expected Domestic vs. International Pharmaceutical Value Share (%), 2019
Figure 9-7: Russia – Estimated  Generics Drug Market (US$ Billion), 2018 - 2026
Figure 9-8: Russia – Share of Generics in the Total Pharmaceutical Market (%), 2018
Figure 9-9: Russia – Average Cost of Branded v/s Generic Drug (US$), 2019
Figure 9-10: Russia –Generic Drugs v/s Branded Drug Package Sales Volume (%), 2019
Figure 10-1: South Korea – Population Enrolled vs. Not Enrolled under National Health Insurance, 2018
Figure 10-2: South Korea – Population Enrolled vs. Not Enrolled under National Health Insurance (%), 2018
Figure 11-1: Key Factors for Low Pricing of the Generic Drugs in the Market
Figure 12-1: Letrozole – FDA & First Generic Approval Year
Figure 12-2: Letrozole – Price for a Supply of 30 Tablets & Price per Unit Tablet (US$), 2020’January
Figure 12-3: Letrozole – Price for a Supply of 50 Tablets & Price per Unit Tablet (US$), 2020’January
Figure 12-4: Letrozole – Price for a Supply of 90 Tablets & Price per Unit Tablet (US$), 2020’January
Figure 12-5: Letrozole – Price for a Supply of 1000 Tablets & Price per Unit Tablet (US$), 2020’January
Figure 12-6: Letrozole – Price Comparison of 30 Tablets Supply of Branded & Generic Letrozole (US$), 2020’January
Figure 12-7: Letrozole – Daily, Monthly & Annual Treatment Cost using Branded & Generic Letrozole (US$), 2020’January
Figure 12-8: Anastarzole - FDA & Generic Approval Year
Figure 12-9: Anastrazole - Price for a Supply of 6 Tablets & Price per Unit Tablet (US$), 2020’January
Figure 12-10: Anastrazole - Price for a Supply of 15 Tablets & Price per Unit Tablet (US$), 2020’January
Figure 12-11: Anastrazole – Average Price for a Supply of 30 Tablets & Price per Unit Tablet (US$), 2020’January
Figure 12-12: Anastrazole - Price for a Supply of 50 Tablets & Price per Unit Tablet (US$), 2020’January
Figure 12-13: Anastrazole – Average Price for a Supply of 90 Tablets & Price per Unit Tablet (US$), 2020’January
Figure 12-14: Anastrazole - Price for a Supply of 500 Tablets & Price per Unit Tablet (US$), 2020’January
Figure 12-15: Anastrazole - Price for a Supply of 1000 Tablets & Price per Unit Tablet (US$), 2020’January
Figure 12-16: Anastrazole – Price Comparison of 30 Tablets Supply of Branded & Generic Anastrazole (US$), 2020’January
Figure 12-17: Letrozole – Daily, Monthly & Annual Treatment Cost for Breast Cancer (US$), 2020’January
Figure 12-18: Armidex – Daily, Monthly & Annual Treatment Cost for Breast Cancer (US$), 2020’January
Figure 12-19: Exemestane - FDA & First Generic Approval Year
Figure 12-20: Exemestane – Price Comparison of 30 Tablets of Branded & Generic Exemestane (US$), 2020’January
Figure 12-21: Exemestane - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020’January
Figure 12-22: Aromasin - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020’January
Figure 12-23: Epirubicine - FDA & First Generic Approval Year
Figure 12-24: Epirubicine – Average Price for a Supply of 25ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 12-25: Epirubicine – Average Price for a Supply of 100ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 12-26: Ellence – Average Price for a Supply of 25ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 12-27: Ellence – Average Price for a Supply of 100ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 12-28: Epirubicine – Minimum & Maximum Duration of Breast Cancer Treatment (Weeks), January’2020
Figure 12-29: Epirubicine – Average Cost of Single Treatment Cycle and Full Treatment using 120/m2 Dose Regimen (US$), January’2020
Figure 12-30: Ellence – Average Cost of Single Treatment Cycle and Full Treatment using 120/m2 Dose Regimen (US$), January’2020
Figure 12-31: Epirubicine – Average Cost of Single Treatment Cycle and Full Treatment using 100/m2 Dose Regimen (US$), January’2020
Figure 12-32: Ellence – Average Cost of Single Treatment Cycle and Full Treatment using 100/m2 Dose Regimen (US$), January’2020
Figure 12-33: Toremifene - FDA & First Generic Approval Year
Figure 12-34: Toremifene – Price Comparison of 30 Tablets of Branded & Generic Toremifene (US$), 2020’January
Figure 12-35: Toremifene - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020’January
Figure 12-36: Fareston - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020’January
Figure 12-37: Fulvestrant - FDA & First Generic Approval Year
Figure 12-38: Fulvestrant – Average Price for a Supply of 10ml, 5ml & Price per ml of Intramuscular Solution (US$), January’2020
Figure 12-39: Faslodex – Average Price for a Supply of 10ml, 5ml & Price per ml of Intramuscular Solution (US$), January’2020
Figure 12-40: Fulvestrant – Number of Dose Administration in Initial & Subsequent Months, January’2020
Figure 12-41: Fulvestrant – Treatment Cost of Initial & Subsequent Months (US$), January’2020
Figure 12-42: Fulvestrant – Treatment Cost of Initial & Subsequent Year (US$), January’2020
Figure 12-43: Faslodex – Treatment Cost of Initial & Subsequent Months (US$), January’2020
Figure 12-44: Faslodex – Treatment Cost of Initial & Subsequent Year (US$), January’2020
Figure 12-45: Megastrol - FDA & Generic Approval Year
Figure 12-46: Megastrol – Price for Various Supplies of 40mg/ml Oral Suspension (US$), January’2020
Figure 12-47: Megastrol - Price for Supply of 150 ml & Price per ml of 625mg/5ml Oral Suspension (US$), January’2020
Figure 12-48: Megace ES - Price for Supply of 150 ml & Price per ml of 625mg/5ml Oral Suspension (US$), January’2020
Figure 12-49: Megastrol - Price for Supply of 100 Tablets & Price per Unit of 20mg Tablet (US$), January’2020
Figure 12-50: Megastrol - Price for Supply of 100, 250 & 500 Tablets of 40mg (US$), January’2020
Figure 12-51: Megestrol - Average Cost of Daily, Monthly & Annual Treatment using 40mg/ml Oral Suspension (US$), 2020’January
Figure 12-52: Megestrol - Average Cost of Daily, Monthly & Annual Treatment using 40mg Oral Tablet (US$), 2020’January
Figure 13-1: Irinotecan - FDA & First Generic Approval Year
Figure 13-2: Irinotecan – Price Comparison of 2ml Branded & Generic Intravenous Solution (US$), 2020’January
Figure 13-3: Irinotecan – Price Comparison of 5 ml Intravenous Branded & Generic Solution (US$), 2020’January
Figure 13-4: Irinotecan – Price of 25ml & Price per ml of Intravenous Solution (US$), 2020’January
Figure 13-5: Captostar – Price of 15ml & Price per ml of Intravenous Solution (US$), 2020’January
Figure 13-6: Irinotecan – Minimum & Maximum Duration of Treatment Cycle (Weeks), January ’2020
Figure 13-7: Irinotecan – Cost of Single Treatment Cycle using Branded & Generic Irinotecan Intravenous Solution (US$), January ’2020
Figure 13-8: Oxaliplatin - FDA & First Generic Approval Year
Figure 13-9: Oxaliplatin – Price of 50 mg & 100 mg Intravenous Powder for Injection (US$), 2020’January
Figure 13-10: Oxaliplatin – Price of 10ml & 1ml Intravenous Solution for Injection (US$), 2020’January
Figure 13-11: Oxaliplatin – Price of 20ml, 100ml & 200 ml Intravenous Solution for Injection (US$), 2020’January
Figure 13-12: Eloxatin – Price of 10ml & 1ml Intravenous Solution for Injection (US$), 2020’January
Figure 13-13: Eloxatin – Price of 20ml & 1ml Intravenous Solution for Injection (US$), 2020’January
Figure 13-14: Oxaplatin – Duration of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (Weeks), 2020’January
Figure 13-15: Oxaplatin Powder – Average Cost of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (US$), 2020’January
Figure 13-16: Oxaplatin Solution – Average Cost of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (US$), 2020’January
Figure 13-17: Eloxatin – Average Cost of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (US$), 2020’January
Figure 14-1: Clofarabin - FDA & First Generic Approval Year
Figure 14-2: Clofarabin - Price Comparison of 20 ml Branded & Generic Intravenous Solution (US$), 2020’January
Figure 14-3: Clofrabin – Average cost of Single Treatment Cycle using Branded & Generic Solution (US$), january’2020
Figure 14-4: Imatinib - FDA & First Generic Approval Year
Figure 14-5: Imatinib – Price of 20 Tablets & Price per Unit of 100mg Tablet (US$), 2020’January
Figure 14-6: Imatinib – Price of 30 Tablets & Price per Unit of 100mg Tablet (US$), 2020’January
Figure 14-7: Imatinib – Average Price of 90 Tablets & Price per Unit of 100mg Tablet (US$), 2020’January
Figure 14-8: Imatinib – Average Price of 20 & 30 Tablets Supply of 400mg Tablet (US$), 2020’January
Figure 14-9: Gleevec – Price of 90 Tablets & Price per Unit of 100mg Tablet (US$), 2020’January
Figure 14-10: Gleevec – Price of 30 Tablets & Price per Unit of 400mg Tablet (US$), 2020’January
Figure 14-11: Imatinib – Dose in Chronic & Accelerated Phase of Mylogenous Leukemia (mg), January’2020
Figure 14-12: Imatinib – Chronic Phase Treatment Cost Comparison using Branded & Generic Tablet (US$), January’2020
Figure 14-13: Imatinib – Accelerated Phase Treatment Cost Comparison using Branded & Generic Tablet (US$), January’2020
Figure 14-14: Mercaptopurine - FDA & First Generic Approval Year
Figure 14-15: Mercaptopurine – Price of 25 Tablets & Price per Unit of 50mg Tablet (US$), 2020’January
Figure 14-16: Mercaptopurine – Price of 250 Tablets & Price per Unit of 50mg Tablet (US$), 2020’January
Figure 14-17: Mercaptopurine – Daily, Monthly & Annual Treatment Cost of ALL (US$), January’2020
Figure 14-18: Idarubicin - FDA & First Generic Approval Year
Figure 14-19: Idarubicine – Price Comparison of 5ml Intravenous Branded & Generic Solution (US$), 2020’January
Figure 14-20: Idarubicine – Price Comparison of 10ml Intravenous Branded & Generic Solution (US$), 2020’January
Figure 14-21: Idarubicine – Price Comparison of 20ml Intravenous Branded & Generic Solution (US$), 2020’January
Figure 14-22: Idarubicin – Dialy & Maximum Cumulative Lifetime Dose (mg/m2), January’2020
Figure 14-23: Idarubicin – Comparison of Dialy & Full Treatment Cost using Branded & Generic Tablet (US$), January’2020
Figure 14-24: Cerubidine - FDA & First Generic Approval Year
Figure 14-25: Daunorubicin – Price of 10 ml Supply & Price per ml of Intravenous Solution (US$), 2020’February
Figure 14-26: Daunorubicin – Price of 40 ml Supply & Price per ml of Intravenous Solution (US$), 2020’February
Figure 14-27: Daunorubicin – Number of Dose Administration in Initial & Subsequent Cycle for Acute Nonlymphocytic Leukemia, 2020’February
Figure 14-28: Daunorubicin – Adult Dose for Acute Nonlymphocytic Leukemia by Age Group (mg/m2), 2020’February
Figure 14-29: Daunorubicin – Cost of Single Dose for Nonlymphocytic Leukemia by Age Group (US$), 2020’February
Figure 14-30: Cytarabin – Price for 25ml & 50ml Supply of 20mg/ml Intravenous Solution (US$), 2020’February
Figure 14-31 Cytarabin – Price for 20ml Supply of 100mg/ml Intravenous Solution (US$), 2020’February
Figure 14-32: Cytarabin – Average Minimum & Maximum Cost of Daily Treatment of Acute Nonlymphocytic Leukemia (US$), 2020’February
Figure 14-33: Cytarabin – Average Daily & Full Treatment Cost in Initial Phase of Meningeal Leukemia (US$), 2020’February
Figure 15-1: Abiraterone - FDA & First Generic Approval Year
Figure 15-2: Aberaterone – Price of 30 Tablets & Price per unit of 250mg Tablet (US$), 2020’January
Figure 15-3: Aberaterone – Price of 120 Tablets & Price per Unit of 250mg Tablet (US$), 2020’January
Figure 15-4: Zytiga – Price of 120 Tablets & Price per unit of 250mg Tablet (US$), 2020’January
Figure 15-5: Zytiga – Price of 60 Tablets & Price per Unit of 500mg Tablet (US$), 2020’January
Figure 15-6: Abiraterone – Treatment Cost Comparison of Metastatic High-risk CSPC using Branded & Generic Tablet (US$), January’2020
Figure 15-7: Abiraterone – Treatment Cost Comparison of Metastatic CSPC using Branded & Generic Tablet (US$), January’2020
Figure 15-8: Bicalutamide - FDA & First Generic Approval Year
Figure 15-9: Bicalutamide - Price Comparison of 30 Tablets of Branded & Generic Bicalutamide (US$), 2020’January
Figure 15-10: Bicalutamide – Price of 100 Tablets & Price per Unit of 50mg Tablet (US$), 2020’January
Figure 15-11: Bicalutamide – Price of 500 Tablets & Price per Unit of 50mg Tablet (US$), 2020’January
Figure 15-12: Bicalutamide – Treatment Cost Comparison of Prostate Cancer using Branded & Generic Tablet (US$), January’2020
Figure 15-13: Nilutamide - FDA & First Generic Approval Year
Figure 15-14: Nilutamide - Price Comparison of 30 Tablets of Branded & Generic Nilutamide (US$), 2020’January
Figure 15-15: Nilutamide – Initial & Maintenance Dose for Prostate Cancer Treatment (mg/day), January’2020
Figure 15-16: Nilutamide – Comparison of Initial Month Treatment Cost of Prostate Cancer using Branded & Generic Tablet (US$), January’2020
Figure 15-17: Nilutamide – Comparison of Maintenance Month Treatment Cost of Prostate Cancer using Branded & Generic Tablet (US$), January’2020
Figure 15-18: Flutamide - FDA & First Generic Approval Year
Figure 15-19: Flutamide - Price Comparison of 180 Capsules of Branded & Generic Flutamide (US$), 2020’January
Figure 15-20: Flutamide – Comparison of Daily, Monthly & Annual Treatment of Prostate Cancer using Branded & Generic Capsule (US$), January’2020
Figure 16-1: Aldara - FDA & First Generic Approval Year
Figure 16-2: Imiquimod – Price for a Supply of 12 Creams & Price per Unit of 5% Topical Cream (US$), 2020’January
Figure 16-3: Imiquimod – Price for a Supply of 24 Creams & Price per Unit of 5% Topical Cream (US$), 2020’January
Figure 16-4: Aldara – Price for a Supply of 12 Creams & Price per Unit of 5% Topical Cream (US$), 2020’January
Figure 16-5: Imiquimod - Duration of Single Treatment Cycle & Full Treatment of Basal Cell Carcinoma (Weeks), January’2020
Figure 16-6: Imiquimod – Comparison of Single Treatment Cycle & Full Treatment using Branded & Generic 5% Cream (US$), January’2020
Figure 16-7: Fluorouracil Cream - FDA & First Generic Approval Year
Figure 16-8: Fluorouracil Solution - FDA & First Generic Approval Year
Figure 16-9: Topical Fluorouracil - Price Comparison of 40gm Branded & Generic Cream (US$), 2020’January
Figure 16-10: Topical Fluorouracil - Price of 10ml Supply & Price per ml of 5% Solution (US$), 2020’January
Figure 16-11: Topical Fluorouracil – Minimum & Maximum Duration for Basal Cell Carcinoma Treatment (Weeks), 2020’January
Figure 17-1: Vinorelbine - FDA & First Generic Approval Year
Figure 17-2: Vinorelbine - Price Comparison of 5ml Supply of Branded & Generic Intravenous Solution (US$), 2020’January
Figure 17-3: Vinorelbine - Price Comparison of 1ml Supply of Branded & Generic Intravenous Solution (US$), 2020’January
Figure 17-4: Vinorelbine Monotherapy – Comparison of Treatment Cost of NSCLC using Branded & Generic Intravenous Solution (US$), January’2020
Figure 17-5: Vinorelbine – Combinational Dose with 100mg/m2 and 120 mg/m2 Cisplatin (mg/m2), January’2020
Figure 18-1: Temozolomide Oral Capsule - FDA & First Generic Approval Year
Figure 18-2: Temozolomide - Price of Various Supplies of 5mg Capsule (US$), 2020’January
Figure 18-3: Temozolomide - Price of Various Supplies of 20mg Capsule (US$), 2020’January
Figure 18-4: Temozolomide - Price of Various Supplies of 100mg Capsule (US$), 2020’January
Figure 18-5: Temozolomide - Price of Various Supplies of 100mg Capsule (US$), 2020’January
Figure 18-6: Temozolomide - Price of 5 Capsules Supply of 180mg & 250mg Dose (US$), 2020’January
Figure 18-7: Temodar - Price of 5 & 14 Capsules Supplies of Different Dose Regimen (US$), 2020’January
Figure 18-8: Temozolomide – Initial & Maintenance Dose for Anaplastic Astrocytoma (mg/m2), 2020’January
Figure 18-9: Temozolomide – Anaplastic Astrocytoma Initial Treatment Cost Comparison using Branded & Generic Capsule (US$), January’2020
Figure 18-10: Temozolomide – Anaplastic Astrocytoma Maintenance Treatment Cost Comparison using Branded & Generic Capsule (US$), January’2020
Figure 18-11: Temozolomide – Gliobastoma Multiforme Treatment Cost Comparison using Branded & Generic Capsule (US$), January’2020
Figure 19-1: Temsirolimus - FDA & First Generic Approval Year
Figure 19-2: Vinorelbine - Price Comparison of 1ml Supply of Branded & Generic Intravenous Solution (US$), 2020’January
Figure 19-3: Temsirolimus– Comparison of Treatment Cost of Renal Cell Carcinoma using Branded & Generic Intravenous Solution (US$), January’2020
Figure 20-1: Erlotinib - FDA & First Generic Approval Year
Figure 20-2: Erlotinib – Price of 20 & 30 Tablets Supply of 25mg Dose (US$), 2020’January
Figure 20-3: Erlotinib – Price of 20 & 30 Tablets Supply of 100mg Dose (US$), 2020’January
Figure 20-4: Erlotinib – Price of 20 & 30 Tablets Supply of 150mg Dose (US$), 2020’January
Figure 20-5: Tarceva – Price for 30 Tablets Supply of 25mg, 100mg & 150mg (US$), 2020’January
Figure 20-6: Erlotinib – Comparison of Treatment Cost of NSCLC using Branded & Generic Tablet (US$), January’2020
Figure 20-7: Erlotinib – Comparison of Treatment Cost of Pancreatic cancer using Branded & Generic Tablet (US$), January’2020
Figure 20-8: Dactinomycin - FDA & First Generic Approval Year
Figure 20-9: Dactinomycin – Price for a Supply 12 and Price for Single Powder for Injection (US$), 2020’January
Figure 20-10: Dactinomycin - Price Comparison of 0.5mg Branded & Generic Powder for Injection (US$), 2020’January
Figure 20-11: Dactinomycin – Cost Comparison of Single Treatment Cycle of Wilm’s Tumor using Branded & Generic Powder for Injection (US$), 2020’January
Figure 20-12: Dactinomycin – Cost Comparison of Testicular Cancer Treatment using Branded & Generic Dactinomycin (US$), January’2020
Figure 20-13: Dactinomycin – Treatment Cost Comparison Lower Extremity Solid Tumor using Branded & Generic Powder for Injection (US$), 2020’January
Figure 20-14: Ifosfamide - FDA & First Generic Approval Year
Figure 20-15: Ifosfamide - Price Comparison of 1gm & 3gm Supply of Branded & Generic Powder for Injection (US$), 2020’January
Figure 20-16: Ifosfamide – Price for a Supply 20ml & 60ml Intravenous Solution for Injection (US$), 2020’January
Figure 20-17: Ifosfamide – Treatment Cost Comparison of  Branded & Generic Powder fo Injection (US$), January’2020
Figure 20-18: Istodax - FDA Approval & Patent Expiration Year
Figure 20-19: Romidepsin - Price Comparison of 10mg Branded & Generic Powder for Injection (US$), 2020’January
Figure 20-20: Remidepsin – Treatment Cost Comparison of Branded & Generic Dactinomycin (US$), January’2020
Figure 20-21: Afinitor - FDA & First Generic Approval Year
Figure 20-22: Evrolimus - Price of 28 Tablets Supplies of Various Dose Regimen (US$), 2020’January
Figure 20-23: Afinitor - Price of 28 Tablets Supplies of Various Dose Regimen (US$), 2020’January
Figure 20-24: Evrolimus – Treatment Cost Comparison of Various Cancers using  Branded & Generic Tablet (US$), January’2020
Figure 20-25: Capecitabine - FDA & First Generic Approval Year
Figure 20-26: Capecitabine – Average Price for a Supply of 60 Tablets & Price per Unit of 150mg Tablet (US$), 2020’January
Figure 20-27: Capecitabine – Average Price for a Supply of 20 Tablets & Price per Unit of 500mg Tablet (US$), 2020’January
Figure 20-28: Capecitabine – Price for a Supply of 30 Tablets & Price per Unit of 500mg Tablet (US$), 2020’January
Figure 20-29: Capecitabine – Average Price for a Supply of 120 Tablets & Price per Unit of 500mg Tablet (US$), 2020’January
Figure 20-30: Capecitabine – Price Comparison of 60 Tablets Supply of 150mg Branded & Generic Capecitabine (US$), 2020’January
Figure 20-31: Capecitabine – Price Comparison of 120 Tablets Supply of 500mg Branded & Generic Capecitabine (US$), 2020’January
Figure 20-32: Capecitabine – Duration of Treatment & Rest Phase in Single Treatment Cycle (Weeks), 2020’January
Figure 20-33: Capecitabine – Comparison of Treatment Cost of Breast Cancer using  Branded & Generic Tablet (US$), January’2020
Figure 20-34: Gemcitabine - FDA & First Generic Approval Year
Figure 20-35: Gemcitabine – Average Price of 200mg, 1gm & 2gm Powder for Injection (US$), 2020’January
Figure 20-36: Gemzar – Average Price of 200mg & 1gm Powder for Injection (US$), 2020’January
Figure 20-37: Gemcitabine – Average Price for Supply of 5.26ml, 26.3ml & 52.6 ml Solution for Injection of 38mg/ml (US$), 2020’January
Figure 20-38: Gemcitabine – Average Price of 2ml, 10ml, 15ml & 20ml Intravenous Solution (US$), 2020’January
Figure 20-39: Gemcitabine – Treatment Cost Comparison of Ovarian Cancer using  Branded & Generic Solution (US$), January’2020
Figure 20-40 Gemcitabine – Treatment Cost Comparison of NSCLC & Breast Cancer using  Branded & Generic Solution (US$), January’2020
Figure 20-41: Taxol - FDA & First Generic Approval Year
Figure 20-42: Paclitaxel - Average Price Various Supplies of Intravenous Solution for Injection (US$), 2020’January
Figure 20-43: Paclitaxel – Dose for Treatment of Breast Cancer, NSCLC & Ovarian Cancer (Mg/m2/3 Weeks), 2020’February
Figure 20-44: Paclitaxel – Average Cost of single Dose & Annual Treatment of Breast Cancer (US$), 2020’February
Figure 20-45: Paclitaxel – Average Cost of Single Dose & Full Treatment of Adjuvant Breast Cancer (US$), 2020’February
Figure 20-46: Adrucil - FDA & First Generic Approval Year
Figure 20-47: Fluorouracil – Average Price of various Supplies of Intravenous Solution (US$), 2020’January
Figure 20-48: Adrucil – Average Price of various Supplies of Intravenous Solution (US$), 2020’January
Figure 20-49: Fluorouracil – Duration of Single Treatment cycle & Full Treatment of Breast Cancer (Weeks), 2020’January
Figure 20-50: Fluorouracil – Treatment Cost Comparison of Breast Cancer using Branded & Generic Intravenous Solution (US$), 2020’January
Figure 20-51: Fluorouracil – Branded v/s Generic Initial Day Treatment Cost Comparison of Colorectal Cancer (US$), 2020’January
Figure 20-52: Fluorouracil – Branded v/s Generic Subsequent Treatment Cycle Cost Comparison of Colorectal Cancer (US$), 2020’January
Figure 20-53: Docetaxel - FDA & First Generic Approval Year
Figure 20-54: Docetaxel – Average Price of Various Supplies of Intravenous Solution of 10mg/ml Dose (US$), 2020’February
Figure 20-55: Docetaxel – Average Price of various Supplies of Intravenous Solution of 20mg/ml Dose (US$), 2020’February
Figure 20-56: Taxotere – Average Price for 1ml & 4 ml Supplies of Intravenous Solution (US$), 2020’February
Figure 20-57: Docetaxel – Treatment Cost Comparison of Branded & Generic Drug for Prostate Cancer & NSCLA (US$), 2020’February
Figure 20-58: Docetaxel Combination – Duration of Single Treatment Cycle & Full Treatment of Breast Cancer (Weeks), 2020’February
Figure 20-59: Docetaxel – Treatment Cost Comparison of Branded & Generic Drug for Breast Cancer Management (US$), 2020’February
Figure 20-60: Methotrexate – Average Price of 10 ml Supply & Price per ml of 25mg/ml Intravenous Solution (US$), 2020’February
Figure 20-61: Methotrexate – Average Price of Different Supplies of Oral Tablet (US$), 2020’February
Figure 20-62: Methotrexate – Minimum & Maximum Duration of Initial Treatment Phase of ALL (Weeks), 2020’February
Figure 20-63: Methotrexate – Single Treatment Cycle Cost in Initial & Maintenance Phase (US$), 2020’February
Figure 20-64: Methotrexate – Minimum & Maximum Treatment Cost of Initial Phase of ALL (US$), 2020’February
Figure 20-65: Methotrexate – Duration of Treatment & Rest Period for Choriocarcinoma Treatment (Days), 2020’February
Figure 20-66: Methotrexate – Minimum & Maximum Treatment Cost of Single Day (US$), 2020’February
Figure 20-67: Methotrexate – Minimum & Maximum Cost of Single Treatment Cycle (US$), 2020’February
Figure 20-68: Cyclophosphamide – Average Price for 1gm, 2gm & 500mg Powder for Injection (US$), 2020’February
Figure 20-69: Cyclophosphamide – Average Price for a Supply of 100 Capsules of 25mg & 50 mg Dose (US$), 2020’February
Figure 20-70: Cyclophosphamide IV Solution – Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US$), 2020’February
Figure 20-71: Cyclophosphamide Capsule – Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US$), 2020’February
Figure 20-72: Vincristine – Average Price for 1ml & 2ml Intravenous Solution (US$), 2020’February
Figure 20-73: Vincristine – Average Cost of Single Cycle, Monthly & Annual Treatment (US$), February’2020
Figure 20-74: Vincristine – Minimum & Maximum Pediatric Dose (mg/m2), February’2020
Figure 20-75: Etoposide - FDA & First Generic Approval Year
Figure 20-76: Etoposide – Price for a Supply of 5 ml, 25 ml & 50 ml Supply of Intravenous Solution (US$), February’2020
Figure 20-77: Etoposide – Price for a Supply of 20 Tablets & Price per Unit of 50 mg Tablet (US$), February’2020
Figure 20-78: Etoposide – Minimum & Maximum Duration of Single Treatment Cycle of SCLC (Weeks), February’2020
Figure 20-79: Etoposide – Average Cost of Daily Treatment & One Treatment Cycle of SCLC (US$), February’2020
Figure 20-80: Etoposide – Minimum & Maximum Cost of Single Treatment Cycle of Testicular Cancer (US$), February’2020
Figure 20-81: Mitoxantrone - FDA & First Generic Approval Year
Figure 20-82: Mitoxantrone – Price for a Supply of 10 ml, 12.5 ml & 15 ml Supply of Intravenous Solution (US$), February’2020
Figure 20-83: Mitoxantrone – Average Cost of Single Treatment Cycle & Annual Treatment of Prostate Cancer (US$), February’2020
Figure 20-84: Mitoxantrone – Average Cost of Induction & Consolidation Phase for Acute Non-Lymphocytic Leukemia (US$), February’2020
Figure 20-85: Carmustine - FDA & First Generic Approval Year
Figure 20-86: Carmustine – Branded v/s Generic Price Comparison of 100mg Dose (US$), February’2020
Figure 20-87: Etoposide – Minimum & Maximum Cost of Single Treatment Cycle (US$), February’2020
Figure 20-88: BiCNU – Minimum & Maximum Cost of Single Treatment Cycle (US$), February’2020
Figure 20-89: Dacarbazine - FDA & First Generic Approval Year
Figure 20-90: Dacarbazine – Price for a Supply of 10 & Price per Unit of 100 mg Powder for Injection (US$), February’2020
Figure 20-91: Dacarbazine – Price for a Supply of 20 & Price per Unit of 200 mg Powder for Injection (US$), February’2020
Figure 20-92: Dacarbazine – Minimum & Maximum Dose for Malignant Melanoma (mg/m2/day), February’2020
Figure 20-93: Dacarbazine – Minimum & Maximum Cost of One Treatment Cycle for Malignant Melanoma (US$), February’2020
Figure 20-94: Dacarbazine – Cost of Single Dose & Single Treatment Cycle for Malignant Melanoma (US$), February’2020
Figure 20-95: Miytomycin - FDA & First Generic Approval Year
Figure 20-96: Mitomycin – Price for Supply of Single 5mg, 20 mg & 40 mg Powder for Injection (US$), February’2020
Figure 20-97: Mutamycin – Price for Supply of Single 5mg, 20 mg & 40 mg Powder for Injection (US$), February’2020
Figure 20-98: Mitomycin – Minimum & Maximum Duration of Single Treatment Cycle (Weeks), February’2020
Figure 20-99: Mitomycin – Branded v/s Generic Cost Comparison of Single Treatment Cycle (US$), February’2020
Figure 20-100: Bleomycin - FDA & First Generic Approval Year
Figure 20-101: Bleomycin – Price for Supply of Single 15 Units & 30 Units Powder for Injection (US$), February’2020
Figure 20-102: Bleomycin – Minimum & Maximum Cost for Single Once a Week Treatment Cycle (US$), February’2020
Figure 20-103: Bleomycin – Minimum & Maximum Cost for Single Twice a Week Treatment Cycle (US$), February’2020

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Accord Healthcare
  • Akorn Pharmaceuticals
  • Alkem Laboratories
  • Alvogen
  • Amneal Pharmaceuticals
  • Apotex
  • Bedford Pharma
  • Cipla
  • Dr. Reddy Laboratories
  • Endo Pharma
  • Fresenius Kabi
  • Gland
  • Glenmark
  • HBT Labs
  • Hikma
  • MSN Group
  • Mayne Pharma
  • Mylan
  • Neopharm
  • Netco
  • Pfizer (Hospira)  
  • Qilu Pharmaceuticals
  • Rising Pharma
  • Shilpa Medicare
  • Sun Pharma
  • Taro Pharmaceuticals
  • Teva Pharmaceuticals
  • Wockhardt
  • Zydus Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll